The phase 3 CABINET trial evaluated cabozantinib versus placebo in patients with previously treated neuroendocrine tumors. Data from this trial showed significant improvement in progression-free survival (PFS) with cabozantinib in both pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET) cohorts.
In the pNET cohort, cabozantinib led to a median PFS of 13.8 months compared to 4.4 months with placebo. For epNET, median PFS was 8.4 months with cabozantinib and 3.9 months with placebo.
Additional analyses revealed benefits with cabozantinib across various clinical subgroups, including primary tumor site, grade, and prior systemic therapy. The objective response rate (ORR) was 19% in the pNET cohort and 5% in the epNET cohort, indicating tumor shrinkage in patients receiving cabozantinib.
Interim overall survival (OS) results were similar between cabozantinib and placebo, with hazard ratios of 0.95 for pNET and 0.86 for epNET.
The CABINET study enrolled a diverse patient population, reflecting real-world clinical practice. The final results published in the New England Journal of Medicine support the potential role of cabozantinib as a new standard of care for patients with advanced neuroendocrine tumors.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
